Susquehanna International Group
AQST icon

Susquehanna International Group’s Aquestive Therapeutics AQST Stock Holding History

Susquehanna International Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
337,635
-249,614
-43% -$1.01M ﹤0.01% 7064
2025
Q4 		$3.79M Sell
587,249
-501,395
-46% -$3.12M ﹤0.01% 4491
2025
Q3 		$6.09M Buy
1,088,644
+621,883
+133% +$2.69M ﹤0.01% 3780
2025
Q2 		$1.54M Buy
466,761
+181,119
+63% +$520K ﹤0.01% 6366
2025
Q1 		$828K Buy
285,642
+91,768
+47% +$278K ﹤0.01% 7729
2024
Q4 		$690K Buy
193,874
+38,842
+25% +$179K ﹤0.01% 7856
2024
Q3 		$772K Buy
155,032
+78,213
+102% +$304K ﹤0.01% 7419
2024
Q2 		$200K Sell
76,819
-525,170
-87% -$1.75M ﹤0.01% 10360
2024
Q1 		$2.56M Buy
601,989
+563,732
+1,474% +$1.88M ﹤0.01% 4819
2023
Q4 		$77.3K Buy
38,257
+26,040
+213% +$46K ﹤0.01% 11501
2023
Q3 		$18.7K Sell
12,217
-80,982
-87% -$139K ﹤0.01% 11619
2023
Q2 		$154K Sell
93,199
-23,073
-20% -$41.7K ﹤0.01% 10554
2023
Q1 		$133K Buy
+116,272
New +$101K ﹤0.01% 11033
2022
Q4 		– Sell
-23,850
Closed -$28K – 12332
2022
Q3 		$28K Buy
+23,850
New +$27K ﹤0.01% 12468
2022
Q2 		– Sell
-48,511
Closed -$126K – 12818
2022
Q1 		$126K Sell
48,511
-118,928
-71% -$347K ﹤0.01% 11732
2021
Q4 		$651K Buy
167,439
+106,165
+173% +$533K ﹤0.01% 8447
2021
Q3 		$267K Sell
61,274
-39,036
-39% -$153K ﹤0.01% 10850
2021
Q2 		$398K Sell
100,310
-29,563
-23% -$118K ﹤0.01% 10147
2021
Q1 		$675K Buy
129,873
+66,699
+106% +$355K ﹤0.01% 8761
2020
Q4 		$338K Sell
63,174
-63,438
-50% -$380K ﹤0.01% 9035
2020
Q3 		$615K Buy
+126,612
New +$828K ﹤0.01% 7243
2020
Q2 		– Sell
-98,610
Closed -$454K – 10072
2020
Q1 		$216K Buy
98,610
+64,210
+187% +$244K ﹤0.01% 8550
2019
Q4 		$200K Buy
+34,400
New +$179K ﹤0.01% 8765

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's AQST Position: Q1 2026 in Review

Susquehanna International Group reduced its Aquestive Therapeutics (AQST) stake by 43% in Q1 2026, selling an estimated $1.01M and leaving 337,635 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #7064.

Susquehanna International Group first reported a position in AQST in Q4 2019 and has held it in 23 quarters since. The position peaked at $6.09M in Q3 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Susquehanna International Group held 337,635 shares of Aquestive Therapeutics worth $1.4M as of Q1 2026.
  • Susquehanna International Group sold 249,614 Aquestive Therapeutics shares in Q1 2026, an estimated $1.01M.
  • Aquestive Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7064 holding.
  • Susquehanna International Group first reported a position in Aquestive Therapeutics in Q4 2019 and has held it in 23 quarters since.
  • Susquehanna International Group's Aquestive Therapeutics position peaked at $6.09M in Q3 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.